Free Trial

Aptamer Group (APTA) Competitors

GBX 0.56 +0.05 (+10.50%)
As of 08/8/2025 12:57 PM Eastern

APTA vs. OKYO, SAR, AREC, AOR, RLM, POLB, NSCI, IXI, OBD, and OPTI

Should you be buying Aptamer Group stock or one of its competitors? The main competitors of Aptamer Group include OKYO Pharma (OKYO), Sareum (SAR), Arecor Therapeutics (AREC), AorTech International (AOR), Realm Therapeutics (RLM), Poolbeg Pharma (POLB), NetScientific (NSCI), IXICO (IXI), Oxford BioDynamics (OBD), and OptiBiotix Health (OPTI). These companies are all part of the "biotechnology" industry.

Aptamer Group vs. Its Competitors

OKYO Pharma (LON:OKYO) and Aptamer Group (LON:APTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

OKYO Pharma has a net margin of 0.00% compared to Aptamer Group's net margin of -343.95%. Aptamer Group's return on equity of -205.63% beat OKYO Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
OKYO PharmaN/A -397.13% -154.72%
Aptamer Group -343.95%-205.63%-44.96%

In the previous week, OKYO Pharma's average media sentiment score of 0.00 equaled Aptamer Group'saverage media sentiment score.

Company Overall Sentiment
OKYO Pharma Neutral
Aptamer Group Neutral

OKYO Pharma has higher earnings, but lower revenue than Aptamer Group. Aptamer Group is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OKYO PharmaN/AN/A-£6.70M-£0.01N/A
Aptamer Group£4.12M2.69-£14.17M-£0.71-0.78

11.7% of Aptamer Group shares are owned by institutional investors. 31.9% of OKYO Pharma shares are owned by insiders. Comparatively, 13.2% of Aptamer Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

OKYO Pharma has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Comparatively, Aptamer Group has a beta of -0.52, meaning that its share price is 152% less volatile than the S&P 500.

Summary

OKYO Pharma and Aptamer Group tied by winning 5 of the 10 factors compared between the two stocks.

Get Aptamer Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for APTA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APTA vs. The Competition

MetricAptamer GroupBiotechnology IndustryMedical SectorLON Exchange
Market Cap£11.09M£137.45M£5.52B£3.07B
Dividend YieldN/A3.74%4.60%5.03%
P/E Ratio-0.783.7830.01170.60
Price / Sales2.694,424.80450.05303,757.13
Price / CashN/A13.1936.7727.96
Price / Book2.6139.278.184.52
Net Income-£14.17M-£90.99M£3.26B£5.90B
7 Day Performance55.87%2.15%6.13%1.23%
1 Month Performance47.62%3.15%0.07%3.22%
1 Year Performance123.20%183.58%36.31%60.28%

Aptamer Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APTA
Aptamer Group
N/AGBX 0.56
+10.5%
N/A+106.7%£11.09M£4.12M-0.7837Gap Up
High Trading Volume
OKYO
OKYO Pharma
N/AN/AN/AN/A£23.24MN/A-140.007Gap Down
SAR
Sareum
N/AGBX 17.88
+5.2%
N/A-45.4%£22.34MN/A-4.233,211Gap Up
AREC
Arecor Therapeutics
N/AGBX 56.98
+0.8%
N/A-34.6%£21.51M£6.04M-2.0110Gap Up
AOR
AorTech International
N/AN/AN/AN/A£19.99M£539K-33.383
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92K-0.66N/A
POLB
Poolbeg Pharma
N/AGBX 2.60
-1.9%
N/A-78.4%£13.36MN/A0.0012
NSCI
NetScientific
N/AN/AN/AN/A£12.81M£1.45M-486.3626
IXI
IXICO
N/AGBX 12.80
+4.5%
N/A+63.3%£11.86M£11.50M-3.3289Gap Up
OBD
Oxford BioDynamics
N/AGBX 0.59
-1.7%
N/A-93.1%£11.12M£5.75M-0.1045
OPTI
OptiBiotix Health
N/AGBX 11.08
-1.6%
N/A-61.1%£10.85M£590.01K-3.511

Related Companies and Tools


This page (LON:APTA) was last updated on 8/10/2025 by MarketBeat.com Staff
From Our Partners